5-Ethynyl-2'-deoxyuridine (EdU) and 5-ethynyl-2'-deoxycytidine (EdC) are mainly used as markers of cellular replicational activity. Although EdU is employed as a replicational marker more frequently than EdC, its cytotoxicity is commonly much higher than the toxicity of EdC. To reveal the reason of the lower cytotoxicity of EdC, we performed a DNA analysis of five EdC-treated human cell lines. Surprisingly, not a single one of the tested cell lines contained a detectable amount of EdC in their DNA. Instead, the DNA of all the cell lines contained EdU. The content of incorporated EdU differed in particular cells and EdC-related cytotoxicity was directly proportional to the content of EdU. The results of experiments with the targeted inhibition of the cytidine deaminase (CDD) and dCMP deaminase activities indicated that the dominant role in the conversion pathway of EdC to EdUTP is played by CDD in HeLa cells. Our results also showed that the deamination itself was not able to effectively prevent the conversion of EdC to EdCTP, the conversion of EdC to EdCTP occurs with much lesser effectivity than the conversion of EdU to EdUTP and the EdCTP is not effectively recognized by the replication complex as a substrate for the synthesis of nuclear DNA.

Institute of Molecular and Translational Medicine Palacký University in Olomouc Olomouc 77900 Czech Republic

Institute of Organic Chemistry and Biochemistry The Czech Academy of Sciences v v i Prague 16610 Czech Republic

Zobrazit více v PubMed

De Clercq E, et al. 1982. Antiviral, antimetabolic, and cytotoxic activities of 5-substituted 2′-deoxycytidines. Mol. Pharmacol. 21, 217–223. PubMed

De Clercq E, Descamps J, De Somer P, Barr PJ, Jones AS, Walker RT. 1979. (E)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proc. Natl Acad. Sci. USA 76, 2947–2951. (doi:10.1073/pnas.76.6.2947) PubMed DOI PMC

Guo J, Li D, Bai S, Xu T, Zhou Z, Zhang Y. 2012. Detecting DNA synthesis of neointimal formation after catheter balloon injury in GK and in Wistar rats: using 5-ethynyl-2′-deoxyuridine. Cardiovasc. Diabetol. 11, 150 (doi:10.1186/1475-2840-11-150) PubMed DOI PMC

Hoshi O, Ushiki T. 2011. Replication banding patterns in human chromosomes detected using 5-ethynyl-2′-deoxyuridine incorporation. Acta Histochem. Cytochem. 44, 233–237. (doi:10.1267/ahc.11029) PubMed DOI PMC

Qu D, Wang G, Wang Z, Zhou L, Chi W, Cong S, Ren X, Liang P, Zhang B. 2011. 5-Ethynyl-2′-deoxycytidine as a new agent for DNA labeling: detection of proliferating cells. Anal. Biochem. 417, 112–121. (doi:10.1016/j.ab.2011.05.037) PubMed DOI

Talarek N, Petit J, Gueydon E, Schwob E. 2015. EdU incorporation for FACS and microscopy analysis of DNA replication in budding yeast. Methods Mol. Biol. 1300, 105–112. (doi:10.1007/978-1-4939-2596-4_7) PubMed DOI

Salic A, Mitchison TJ. 2008. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc. Natl Acad. Sci. USA 105, 2415–2420. (doi:10.1073/pnas.0712168105) PubMed DOI PMC

Ageno M, Dore E, Frontali C. 1969. The alkaline denaturation of DNA. Biophys J. 9, 1281–1311. (doi:10.1016/S0006-3495(69)86452-0) PubMed DOI PMC

Dimitrova DS, Berezney R. 2002. The spatio-temporal organization of DNA replication sites is identical in primary, immortalized and transformed mammalian cells. J. Cell Sci. 115, 4037–4051. (doi:10.1242/jcs.00087) PubMed DOI

Jackson DA, Pombo A. 1998. Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. J. Cell Biol. 140, 1285–1295. (doi:10.1083/jcb.140.6.1285) PubMed DOI PMC

Kennedy BK, Barbie DA, Classon M, Dyson N, Harlow E. 2000. Nuclear organization of DNA replication in primary mammalian cells. Genes Dev. 14, 2855–2868. (doi:10.1101/gad.842600) PubMed DOI PMC

Ligasova A, Liboska R, Rosenberg I, Koberna K. 2015. The fingerprint of anti-bromodeoxyuridine antibodies and its use for the assessment of their affinity to 5-bromo-2′-deoxyuridine in cellular DNA under various conditions. PLoS ONE 10, e0132393 (doi:10.1371/journal.pone.0132393) PubMed DOI PMC

Ligasova A, Strunin D, Liboska R, Rosenberg I, Koberna K. 2012. Atomic scissors: a new method of tracking the 5-bromo-2′-deoxyuridine-labeled DNA in situ. PLoS ONE 7, e52584 (doi:10.1371/journal.pone.0052584) PubMed DOI PMC

Tkatchenko AV. 2006. Whole-mount BrdU staining of proliferating cells by DNase treatment: application to postnatal mammalian retina. Biotechniques 40, 29–32. (doi:10.2144/000112094) PubMed DOI

Zhao H, Dobrucki J, Rybak P, Traganos F, Dorota Halicka H, Darzynkiewicz Z. 2011. Induction of DNA damage signaling by oxidative stress in relation to DNA replication as detected using ‘click chemistry’. Cytometry A 79, 897–902. (doi:10.1002/cyto.a.21137) PubMed DOI PMC

Cristofoli WA, Wiebe LI, De Clercq E, Andrei G, Snoeck R, Balzarini J, Knaus EE. 2007. 5-Alkynyl analogs of arabinouridine and 2′-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. J. Med. Chem. 50, 2851–2857. (doi:10.1021/jm0701472) PubMed DOI

Diermeier-Daucher S, Clarke ST, Hill D, Vollmann-Zwerenz A, Bradford JA, Brockhoff G. 2009. Cell type specific applicability of 5-ethynyl-2′-deoxyuridine (EdU) for dynamic proliferation assessment in flow cytometry. Cytometry A 75, 535–546. (doi:10.1002/cyto.a.20712) PubMed DOI

Kohlmeier F, Maya-Mendoza A, Jackson DA. 2013. EdU induces DNA damage response and cell death in mESC in culture. Chromosome Res. 21, 87–100. (doi:10.1007/s10577-013-9340-5) PubMed DOI PMC

Ligasova A, Strunin D, Friedecky D, Adam T, Koberna K. 2015. A fatal combination: a thymidylate synthase inhibitor with DNA damaging activity. PLoS ONE 10, e0117459 (doi:10.1371/journal.pone.0117459) PubMed DOI PMC

Meneni S, Ott I, Sergeant CD, Sniady A, Gust R, Dembinski R. 2007. 5-Alkynyl-2′-deoxyuridines: chromatography-free synthesis and cytotoxicity evaluation against human breast cancer cells. Bioorg. Med. Chem. 15, 3082–3088. (doi:10.1016/j.bmc.2007.01.048) PubMed DOI PMC

Ross HH, Rahman M, Levkoff LH, Millette S, Martin-Carreras T, Dunbar EM, Reynolds BA, Laywell ED. 2011. Ethynyldeoxyuridine (EdU) suppresses in vitro population expansion and in vivo tumor progression of human glioblastoma cells. J. Neurooncol. 105, 485–498. (doi:10.1007/s11060-011-0621-6) PubMed DOI PMC

Zhao H, Halicka HD, Li J, Biela E, Berniak K, Dobrucki J, Darzynkiewicz Z. 2013. DNA damage signaling, impairment of cell cycle progression, and apoptosis triggered by 5-ethynyl-2′-deoxyuridine incorporated into DNA. Cytometry A 83, 979–988. (doi:10.1002/cyto.a.22396) PubMed DOI PMC

De Clercq E, Descamps J, Huang GF, Torrence PF. 1978. 5-Nitro-2′-deoxyuridine and 5-nitro-2′-deoxyuridine 5′-monophosphate: antiviral activity and inhibition of thymidylate synthetase in vivo. Mol. Pharmacol. 14, 422–430. PubMed

Balzarini J, De Clercq E, Ayusawa D, Seno T. 1985. Incorporation of 5-substituted pyrimidine nucleoside analogues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line. Methods Find Exp. Clin. Pharmacol. 7, 19–28. PubMed

Galmarini CM, Mackey JR, Dumontet C. 2001. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15, 875–890. (doi:10.1038/sj.leu.2402114) PubMed DOI

Liboska R, Ligasova A, Strunin D, Rosenberg I, Koberna K. 2012. Most anti-BrdU antibodies react with 2′-deoxy-5-ethynyluridine—the method for the effective suppression of this cross-reactivity. PLoS ONE 7, e51679 (doi:10.1371/journal.pone.0051679) PubMed DOI PMC

Freshney RI. 2005. Cytotoxicity. In Culture of animal cells. A manual of basic techniques (ed. Freshney RI.), pp. 365–369. Hoboken, NJ: John Wiley and Sons, Inc.

Koberna K, Stanek D, Malinsky J, Eltsov M, Pliss A, Ctrnacta V, Cermanova S, Raska I. 1999. Nuclear organization studied with the help of a hypotonic shift: its use permits hydrophilic molecules to enter into living cells. Chromosoma 108, 325–335. (doi:10.1007/s004120050384) PubMed DOI

Bennett BD, Yuan J, Kimball EH, Rabinowitz JD. 2008. Absolute quantitation of intracellular metabolite concentrations by an isotope ratio-based approach. Nat. Protoc. 3, 1299–1311. (doi:10.1038/nprot.2008.107) PubMed DOI PMC

Carpenter AE, et al. 2006. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (doi:10.1186/gb-2006-7-10-r100) PubMed DOI PMC

Kamentsky L, et al. 2011. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 27, 1179–1180. (doi:10.1093/bioinformatics/btr095) PubMed DOI PMC

Nakayasu H, Berezney R. 1989. Mapping replicational sites in the eucaryotic cell nucleus. J. Cell Biol. 108, 1–11. (doi:10.1083/jcb.108.1.1) PubMed DOI PMC

Koberna K, Malinsky J, Pliss A, Masata M, Vecerova J, Fialova M, Bednar J, Raska I. 2002. Ribosomal genes in focus: new transcripts label the dense fibrillar components and form clusters indicative of ‘Christmas trees’ in situ. J. Cell Biol. 157, 743–748. (doi:10.1083/jcb.200202007) PubMed DOI PMC

de Sousa Cavalcante L, Monteiro G. 2014. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur. J. Pharmacol. 741, 8–16. (doi:10.1016/j.ejphar.2014.07.041) PubMed DOI

Jansen RS, Rosing H, Schellens JH, Beijnen JH. 2011. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? Fundam. Clin. Pharmacol. 25, 172–185. (doi:10.1111/j.1472-8206.2010.00823.x) PubMed DOI

Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. 1992. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 52, 533–539. PubMed

Xu YZ, Plunkett W. 1992. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem. Pharmacol. 44, 1819–1827. (doi:10.1016/0006-2952(92)90077-V) PubMed DOI

Bouffard DY, Laliberte J, Momparler RL. 1993. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol. 45, 1857–1861. (doi:10.1016/0006-2952(93)90444-2) PubMed DOI

Reese ND, Schiller GJ. 2013. High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr. Hematol. Malig. Rep. 8, 141–148. (doi:10.1007/s11899-013-0156-3) PubMed DOI

Hamada A, Kawaguchi T, Nakano M. 2002. Clinical pharmacokinetics of cytarabine formulations. Clin. Pharmacokinet. 41, 705–718. (doi:10.2165/00003088-200241100-00002) PubMed DOI

Gandhi V, Xu YZ, Estey E. 1998. Accumulation of arabinosyluracil 5′-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin. Cancer Res. 4, 1719–1726. PubMed

Momparler RL. 2005. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin. Hematol. 42, S9–S16. (doi:10.1053/j.seminhematol.2005.05.002) PubMed DOI

The kinetics of uracil-N-glycosylase distribution inside replication foci

A new technique for the analysis of metabolic pathways of cytidine analogues and cytidine deaminase activities in cells

Anchored linear oligonucleotides: the effective tool for the real-time measurement of uracil DNA glycosylase activity

DNA Dyes-Highly Sensitive Reporters of Cell Quantification: Comparison with Other Cell Quantification Methods

New Concept and Apparatus for Cytocentrifugation and Cell Processing for Microscopy Analysis

Quantification of fixed adherent cells using a strong enhancer of the fluorescence of DNA dyes

DNA Replication: From Radioisotopes to Click Chemistry